Genmab A/S (NASDAQ:GMAB) Upgraded by BNP Paribas Exane to “Strong-Buy” Rating

BNP Paribas Exane upgraded shares of Genmab A/S (NASDAQ:GMAB) from a hold rating to a strong-buy rating in a report released on Wednesday,Zacks.com reports.

A number of other equities analysts also recently commented on the stock. Jefferies Financial Group initiated coverage on shares of Genmab A/S in a research note on Tuesday, February 17th. They issued a “buy” rating and a $41.50 price objective for the company. Wells Fargo & Company initiated coverage on Genmab A/S in a report on Monday, March 2nd. They issued an “overweight” rating and a $40.00 price target on the stock. Morgan Stanley assumed coverage on Genmab A/S in a research report on Monday, February 16th. They issued an “equal weight” rating and a $34.00 price target for the company. Truist Financial upgraded Genmab A/S to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, HC Wainwright raised their price objective on Genmab A/S from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Genmab A/S presently has a consensus rating of “Moderate Buy” and an average target price of $39.36.

Genmab A/S Stock Up 2.3%

Shares of Genmab A/S stock opened at $27.69 on Wednesday. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. The stock has a market cap of $17.79 billion, a price-to-earnings ratio of 17.86, a PEG ratio of 1.23 and a beta of 0.97. The firm’s 50-day moving average is $27.79 and its two-hundred day moving average is $30.29. Genmab A/S has a 1 year low of $18.89 and a 1 year high of $35.43.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, February 18th. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.46 by ($0.41). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The business had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.06 billion. As a group, research analysts expect that Genmab A/S will post 1.17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Genmab A/S

Several hedge funds have recently modified their holdings of the stock. Paradigm Biocapital Advisors LP acquired a new stake in Genmab A/S in the 3rd quarter worth approximately $117,063,000. Orbis Allan Gray Ltd increased its stake in Genmab A/S by 30.2% during the 4th quarter. Orbis Allan Gray Ltd now owns 14,418,462 shares of the company’s stock valued at $444,089,000 after purchasing an additional 3,340,456 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Genmab A/S by 36.6% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 4,978,058 shares of the company’s stock valued at $153,324,000 after purchasing an additional 1,334,919 shares in the last quarter. Pictet Asset Management Holding SA purchased a new position in shares of Genmab A/S in the fourth quarter worth $33,835,000. Finally, Perpetual Ltd purchased a new position in shares of Genmab A/S in the fourth quarter worth $25,478,000. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.